Anti-metastatic activity of the tumour vascular targeting agent LIGHT-VTP

    NAME Prof. Ruth Ganss
    CANCER TYPE Melanoma
    INSTITUTION The Harry Perkins Institute of Medical Research
    STATE Western Australia
    GRANT TYPE $200,000
    PROJECT TYPE Research

    Anti-metastatic activity of the tumour vascular targeting agent LIGHT-VTP

    "We have developed and patented a new treatment, called LIGHT-VTP therapy, which specifically targets abnormal blood vessels in solid cancers, and brings immune cells right into the cancer core....This project will therefore assess whether LIGHT-VTP therapy can be effective to (i) reduce metastatic spread from primary cancers, (ii) prevent metastatic cancer cells from settling in a distant organ (early metastatic event) and (iii) treat metastases once they have occurred (late stage metastatic disease)"

    - Prof Ruth Ganss, The Harry Perkins Institute of Medical Research